Non-Hodgkin Lymphoma

Diagnosis and Treatment

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. Patients typically present with persistent painless lymphadenopathy, but some patients may present with constitutional symptoms or with involvement of organs other than the lymphoid and hematopoietic system. An accurate diagnosis, careful staging of the disease, and identification of adverse prognostic factors form the basis of treatment selection. Patients commonly receive chemoimmunotherapy as initial treatment, and radiation therapy may be added if patients have early-stage disease. Most patients respond well to treatment, but relapses are frequent and additional therapies including stem cell transplant are often needed. Because many subtypes of lymphoma remain incurable with current management strategies, clinical trials are in progress to identify novel therapies with promising activity in this disease.

Original languageEnglish (US)
Pages (from-to)1152-1163
Number of pages12
JournalMayo Clinic Proceedings
Volume90
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Non-Hodgkin's Lymphoma
Therapeutics
Hematopoietic System
Lymphoma
Radiotherapy
Stem Cells
Clinical Trials
Transplants
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Non-Hodgkin Lymphoma : Diagnosis and Treatment. / Ansell, Stephen Maxted.

In: Mayo Clinic Proceedings, Vol. 90, No. 8, 01.08.2015, p. 1152-1163.

Research output: Contribution to journalArticle

@article{8c5757e81a4e421385f835400d6e83d4,
title = "Non-Hodgkin Lymphoma: Diagnosis and Treatment",
abstract = "Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. Patients typically present with persistent painless lymphadenopathy, but some patients may present with constitutional symptoms or with involvement of organs other than the lymphoid and hematopoietic system. An accurate diagnosis, careful staging of the disease, and identification of adverse prognostic factors form the basis of treatment selection. Patients commonly receive chemoimmunotherapy as initial treatment, and radiation therapy may be added if patients have early-stage disease. Most patients respond well to treatment, but relapses are frequent and additional therapies including stem cell transplant are often needed. Because many subtypes of lymphoma remain incurable with current management strategies, clinical trials are in progress to identify novel therapies with promising activity in this disease.",
author = "Ansell, {Stephen Maxted}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.mayocp.2015.04.025",
language = "English (US)",
volume = "90",
pages = "1152--1163",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Non-Hodgkin Lymphoma

T2 - Diagnosis and Treatment

AU - Ansell, Stephen Maxted

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. Patients typically present with persistent painless lymphadenopathy, but some patients may present with constitutional symptoms or with involvement of organs other than the lymphoid and hematopoietic system. An accurate diagnosis, careful staging of the disease, and identification of adverse prognostic factors form the basis of treatment selection. Patients commonly receive chemoimmunotherapy as initial treatment, and radiation therapy may be added if patients have early-stage disease. Most patients respond well to treatment, but relapses are frequent and additional therapies including stem cell transplant are often needed. Because many subtypes of lymphoma remain incurable with current management strategies, clinical trials are in progress to identify novel therapies with promising activity in this disease.

AB - Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. Patients typically present with persistent painless lymphadenopathy, but some patients may present with constitutional symptoms or with involvement of organs other than the lymphoid and hematopoietic system. An accurate diagnosis, careful staging of the disease, and identification of adverse prognostic factors form the basis of treatment selection. Patients commonly receive chemoimmunotherapy as initial treatment, and radiation therapy may be added if patients have early-stage disease. Most patients respond well to treatment, but relapses are frequent and additional therapies including stem cell transplant are often needed. Because many subtypes of lymphoma remain incurable with current management strategies, clinical trials are in progress to identify novel therapies with promising activity in this disease.

UR - http://www.scopus.com/inward/record.url?scp=84938598515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938598515&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2015.04.025

DO - 10.1016/j.mayocp.2015.04.025

M3 - Article

VL - 90

SP - 1152

EP - 1163

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -